Health Care·Biotechnology·$28.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.46 | N/A | -34.11% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.46 | N/A | -34.11% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed a cautious approach due to the current market conditions. They emphasized their commitment to advancing their pipeline despite the lack of specific guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on its ongoing clinical trials and research efforts.
Revolution Medicines reported a larger-than-expected loss per share, which may raise concerns among investors about profitability. However, the stock rose 8.70%, likely driven by market optimism regarding the company's ongoing clinical trials and research initiatives. The lack of revenue figures and guidance may leave some investors cautious moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
IES HLDGS INC
Aug 7, 2020